NasdaqGM:URGNBiotechs
Assessing UroGen Pharma (URGN) Valuation After Jelmyto Patent Settlement With Teva
UroGen Pharma (URGN) has come into focus after announcing a settlement and license agreement with Teva Pharmaceuticals covering Jelmyto. The deal clarifies future generic entry timing and removes ongoing patent litigation risk around this cancer treatment.
See our latest analysis for UroGen Pharma.
Recent news around Jelmyto has come as the stock cools slightly in the very short term, with the 30 day share price return down 8.67% and the 7 day share price return down 4.55%. This has occurred...